CKD-aP Among Adults on Dialysis in Switzerland (UP-RAISE)

University of Applied Sciences of Western Switzerland

Status: Completed

Conditions: Chronic Kidney Diseases; Dialysis; Chronic Kidney Diseases Associated Pruritus

Treatments: Other: CKD-aP

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT05415969

2022-00670

Details and patient eligibility

About

Chronic Kidney Disease Associated Pruritus (CKD-aP) represents a localized or a generalized skin itch, which is a common symptom occurring in end-stage renal disease and dialysis. The prevalence of CKD-aP in adults on dialysis varies between countries ranging between 20-42%. Swiss data on CKD-aP are unfortunately largely lacking, as Switzerland is so far not part of large registries, such as DOPPS.

The aging population, the increase in diabetes (69% by 2030), the increase in hypertension (60% by 2025) and poly-morbidity will probably lead to a rise in the number of patients on dialysis and subsequent CKD-aP.

CKD-aP is associated with sleep disturbances, compromised quality of life, emotional distress, and increased risks of hospitalization and death. Its management lacks approaches that are supported by strong evidence because its pathogenesis remains poorly understood and may be related to an increase in uremic toxins, skin inflammation. In this context, sweat composition deserves more attention.

Aim of the study The aim of the study is to determine the prevalence of CKD-aP in the population on dialysis, the association between CKD-aP and different electrolytes, and the potential role of the composition of sweat in CKD-aP.

Results will be used for building a CKD-aP symptom management program to improve the quality of care of patients on dialysis and will be incorporated in the nursing continuing education program.

Enrollment: 401 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult ≥ 18 years old
• Diagnosed with end-stage renal disease and receiving hemodialysis for at least 6 months
• Able to communicate in French or availability of a French-speaking close relative for translation
• Signed informed consent

Additional inclusion criteria for the case-control study outcomes phase 2:

• Reporting moderate to severe CKD-aP for the participant considered as a case
• Reporting no or mild CKD-aP for the participant considered as a control Cases and controls will be matched by age-group, sex, and dialysis modality (hemodialysis or peritoneal dialysis).

Exclusion criteria

• Presence of cognitive impairment or cognitive disorder